These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8926800)

  • 1. [Money, hypertension and calcium antagonists].
    Hernborg A
    Lakartidningen; 1996 Sep; 93(39):3348. PubMed ID: 8926800
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 3. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tax payers have payed billions for the "blood pressure maffia's" actions].
    Järhult B; Lindahl SO
    Lakartidningen; 2003 May; 100(21):1917-8. PubMed ID: 12815880
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium channel blockers inferior to cheaper drugs.
    Josefson D
    BMJ; 2000 Sep; 321(7261):590. PubMed ID: 10977828
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):417-8. PubMed ID: 12419166
    [No Abstract]   [Full Text] [Related]  

  • 7. An evaluation of cost variation in different brands of antihypertensive agents.
    Moharana AK; Khurana S; Lal A
    J Assoc Physicians India; 1998 Jun; 46(6):573-4. PubMed ID: 11273270
    [No Abstract]   [Full Text] [Related]  

  • 8. [Are the newer antihypertensive agents better and more effective than diuretics?].
    Landmark K
    Tidsskr Nor Laegeforen; 2001 Feb; 121(6):701-5. PubMed ID: 11293353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comrades! There must be some blood order in the field of hypertension!].
    Melander A
    Lakartidningen; 2005 Apr 4-10; 102(14):1068-70. PubMed ID: 15892478
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
    Amira CO; Okubadejo NU
    J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Following evidence-based prescribing guidelines for antihypertensives could save big bucks.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Jun; 15(11):1, 6-7. PubMed ID: 15241883
    [No Abstract]   [Full Text] [Related]  

  • 14. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 15. [German Hypertension League update. What does the ALLHAT Study really mean?].
    MMW Fortschr Med; 2003 Jun; 145(23):45-6. PubMed ID: 12854226
    [No Abstract]   [Full Text] [Related]  

  • 16. [Argumentation of the NEPI is with invectives and not based on factual matters].
    Frisk M; Strömstedt A
    Lakartidningen; 2000 Oct; 97(42):4772. PubMed ID: 11079336
    [No Abstract]   [Full Text] [Related]  

  • 17. PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists.
    Davies A; Metcalfe S; Moodie P; McNee W
    N Z Med J; 2005 Aug; 118(1220):U1621. PubMed ID: 16132079
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Notes on real and daily cost-efficiency].
    Ortega-Marlasca MM
    Semergen; 2014 Mar; 40(2):115. PubMed ID: 24560996
    [No Abstract]   [Full Text] [Related]  

  • 20. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.